MetSense Risk Flag for Type 2 Diabetes
(MetSense P&F Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
People with serious mental illness have high risk for type 2 diabetes due to multiple risk factors, including the metabolic side effects of psychotropic medications that are used to treat these conditions. Type 2 diabetes is preventable through lifestyle and pharmacological interventions, but many people with serious mental illness do not receive regular screening for type 2 diabetes risk. In many health care settings, clinical pharmacists are increasingly managing patients with serious mental illness and have expertise in monitoring the metabolic side effects of psychotropic medications. This study evaluates the feasibility and acceptability of using a diabetes prediction model that is based on electronic health record data (the MetSense risk flag) to alert clinical pharmacists about patients who are at high diabetes risk, prompting these clinicians to prioritize diabetes risk management services.
Who Is on the Research Team?
Esti Iturralde, PhD
Principal Investigator
KPNC Division of Research
Are You a Good Fit for This Trial?
This trial is for people with serious mental illness who are at high risk of developing type 2 diabetes, often due to the metabolic side effects of their psychiatric medications. It's designed to see if clinical pharmacists can better manage these risks using a special alert system.Inclusion Criteria
What Are the Treatments Tested in This Trial?
Interventions
- MetSense Risk Flag
Find a Clinic Near You
Who Is Running the Clinical Trial?
Kaiser Permanente
Lead Sponsor
National Institute of Mental Health (NIMH)
Collaborator